Equibles does not estimate personal net worth.
Get an email with a short summary when Rhythm Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get RYTM alertsDavid Meeker is recorded as CEO and Chairman at Rhythm Pharmaceuticals, Inc. (RYTM). The proxy statement of Rhythm Pharmaceuticals, Inc. reports total compensation of $17,544,525 for David Meeker in fiscal 2025, including a base salary of $807,692. Disclosed compensation is on record for 6 fiscal years. David Meeker has spoken on 19 earnings calls and 5 other investor events across 1 company, most recently for Rhythm Pharmaceuticals, Inc. on September 15, 2026. Rhythm Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rhythm Pharmaceuticals, Inc. includes David P. Meeker, M.D. (CEO and Chairman), Hunter Smith (CEO and CFO), Christophe R. Jean (Board Member) and 5 others.
“Yeah, so just to set the stage on Rhythm a bit, it's a good moment for the company, for those who are following. And we like to set the company framework up, getting people to think about three pillars.”
“Yeah, it's a great moment for Rhythm, to be honest, as you highlighted some of the headlines there that have come out. So we're into our second quarter of launch on the HO side of the business.”
“Thanks so much, Whitney, and thank you very much to Canaccord Genuity for hosting this terrific conference. We look forward to this every August, and it's a nice way to put a bow on cue too.”
“We have a lot to share today, headlined by a strong start to the U.S. launch of Insivory for Acquired Hypothalamic Obesity, reinforcing our conviction that HO represents a meaningful long-term opportunity for rhythm.”
“Right, we're really looking forward to Saturday. We have our six-month data from the open-label study, an 18-patient study run by Dr. Miller at the University of Florida.”
Biotechnology · Healthcare
CEO, Chairman
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $807,692 | $17,544,525 |
| 2024 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $740,472 | $14,663,742 |
| 2023 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $704,715 | $7,230,457 |
| 2022 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $652,050 | $3,325,758 |
| 2021 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $630,000 | $6,458,360 |
| 2020 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $262,308 | $14,277,367 |
